Injectable implant for the treatment of Vesicoureteral Reflux

Download Catalog
Injectable implant for the treatment of Vesicoureteral Reflux

DEXELL® What is Vesicoureteral Reflux – VUR

Vesicoureteral reflux (VUR) is the retrograde passage of urine from the bladder into the upper urinary tract. It is the most common urological diagnosis in children, occuring in approximately 1 % of newborns and as high as 30 to 45% in children with UTI. Additionally, there is a high association between VUR, UTI, hypertension and renal damage.


Treatment Options

Conventional Low Dose Antibiotic Therapy

  • Extended treatment time

  • Patient/parent non-compliance

  • Risk of antibiotic resistance

  • Break through UTI

Surgical Ureter Reimplantation

  • lnvasive
  • Reimplantation of ureter into bladder

  • High success rate

Endoscopic Dextranomer/Hyaluronic Acid Injection

  • Surgical injection of dextranomer/hyaluronic acid

  • Minimally invasive

  • lmmediate correction of VUR
  • High success rate

Endoscopic correction of VUR offers a minimally invasive, day case procedure with a very low risk of complications compared to open surgery.



  • Non Immunogenic
  • Biocompatible
  • Non allergic
  • Biodegradable by time
  • Long lasting
  • No migration
  • No rigid
DEXELL ® consists of positively charged DEAE dextranomer microspheres (active ingredient) suspended in a cross linked hyaluronic acid gel solution (transporter). Both the dextranomer micro-particles and hyaluronate gel are biocompatible, non-immunogenic and biodegradable.
After initial injection the dextranomer microspheres and hyaluronate gel provide volume. The dextranomer microspheres stimulate collagen synthesis and fibroblast ingrowth into the degrading hyaluronic matrix, consolidating the implant within the bladder wall through endogenous tissue augmentation.
DEXELL® Application
DEXELL ® is suitable to be used with a cystoscopic injection needle in all injection methods e.g. STING and HIT.